Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2−, PIK3CA mutant or wild-type, breast cancer (BC).
Ingrid A. Mayer
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Peter A. Fasching
Consultant or Advisory Role - Genomic Health; Novartis; Roche
Honoraria - Genomic Health; Novartis; Roche
Research Funding - Amgen; Novartis
Michael Gnant
Consultant or Advisory Role - Novartis
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Lars Blumenstein
Employment or Leadership Position - Novartis
Anuradha Dutta
Employment or Leadership Position - Novartis
Caroline Germa
Employment or Leadership Position - Novartis
Rachel Li
Employment or Leadership Position - Novartis
Carlos L. Arteaga
Consultant or Advisory Role - AstraZeneca; Genentech; Monogram Biosciences/LabCorp; Novartis; Roche/Genentech; Susan G. Komen for the Cure
Research Funding - AstraZeneca; OSI Pharmaceuticals; U3 Pharma-Daichi